Patents Assigned to Galderma Laboratories, L.P.
-
Patent number: 10201517Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: GrantFiled: July 27, 2016Date of Patent: February 12, 2019Assignee: Galderma Laboratories, L.P.Inventors: Jean-Christophe Buge, Karine Nadau Fourcade, Cyril Meunier
-
Patent number: 9861632Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.Type: GrantFiled: December 14, 2015Date of Patent: January 9, 2018Assignee: Galderma Laboratories, L.P.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Yin-sang Liu, Matthew James Leoni
-
Patent number: 9861631Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.Type: GrantFiled: April 6, 2015Date of Patent: January 9, 2018Assignee: Galderma Laboratories, L.P.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Yin-sang Liu, Matthew James Leoni
-
Publication number: 20160220565Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: April 6, 2016Publication date: August 4, 2016Applicant: Galderma Laboratories, L.P.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Patent number: 9186358Abstract: Methods and compositions for improved treatment and prevention of an inflammatory skin disorder or a sign and/or symptom associated with the skin disorder are described. The methods involve topical application to the skin a combination of a therapeutically effective amount of an ?2 adrenergic receptor agonist, such as brimonidine, and a therapeutically effective amount of a non-steroidal anti-inflammatory agent, such as diclofenac.Type: GrantFiled: November 18, 2010Date of Patent: November 17, 2015Assignee: GALDERMA LABORATORIES, L.P.Inventors: André Jomard, Françoise Delamadeleine
-
Publication number: 20150202202Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: March 30, 2015Publication date: July 23, 2015Applicant: Galderma Laboratories, L.P.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Patent number: 9072739Abstract: Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an ?2 adrenergic receptor agonist.Type: GrantFiled: March 5, 2013Date of Patent: July 7, 2015Assignee: Galderma Laboratories, L.P.Inventor: Jack A. DeJovin
-
Patent number: 8993571Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: GrantFiled: February 25, 2013Date of Patent: March 31, 2015Assignee: Galderma Laboratories, L.P.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
-
Patent number: 8513249Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.Type: GrantFiled: April 26, 2012Date of Patent: August 20, 2013Assignee: Galderma Laboratories, L.P.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Yin-Sang Liu, Matthew J. Leoni
-
Patent number: 8513247Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.Type: GrantFiled: March 25, 2011Date of Patent: August 20, 2013Assignee: Galderma Laboratories, L.P.Inventors: Michael Graeber, Christian Loesche, Philip Freidenreich, Yin-Sang Liu, Matthew J. Leoni
-
Publication number: 20130184283Abstract: Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an ?2 adrenergic receptor agonist.Type: ApplicationFiled: March 5, 2013Publication date: July 18, 2013Applicant: GALDERMA LABORATORIES, L.P.Inventor: GALDERMA LABORATORIES, L.P.
-
Patent number: 8394800Abstract: Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an ?2 adrenergic receptor agonist, such as brimonidine.Type: GrantFiled: November 19, 2009Date of Patent: March 12, 2013Assignee: Galderma Laboratories, L.P.Inventor: Jack A. DeJovin
-
Publication number: 20110118267Abstract: Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an ?2 adrenergic receptor agonist, such as brimonidine.Type: ApplicationFiled: November 19, 2009Publication date: May 19, 2011Applicant: Galderma Laboratories, L.P.Inventor: Jack A. DeJovin